Drugs Regulator
-
{
- All
- News
- Videos
-
New Study Explains Why Ozempic Doesn't Work For Everyone
A new study published in Genome Medicine details that Ozempic doesn't work for everyone in the same manner. Here is what you need to know about its mechanisms and why making science-based medical decisions is important.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
With Rs 13,000-25,000 Per Dose, Weight-Loss Drugs Are Changing Indian Weddings For Brides
The lowest Mounjaro injection pen dose sells for Rs 13,125 per month, while the highest dose costs Rs 25,781. Novo is selling the lowest Wegovy dose for Rs 5,660 and the highest for Rs 16,400 a month
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Metformin Does More Than Control Blood Sugar: New Research Reveals The Diabetes Drug's Negative Brain Impacts
A new study reveals metformin acts directly on the brain, raising fresh concerns about its wider effects. While effective for diabetes, experts warn of potential cognitive, neurological and metabolic risks, especially with long-term or unsupervised u
-
Common Diabetes Drug Metformin Works By Acting On Brain: Study
While diabetes medications are not considered as targeting the brain, the study, published in the journal Science Advances, shows that metformin has been influencing brain pathways all along, the researchers said.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
"Ozempic Personality" And The Dopamine Shift: The Mental Health Side Effects Of Using Ozempic For Weight Loss
Ozempic personality is a psychological impact of using Ozempic for weight loss. You need to know the possible side effects on your mental health to be careful.
-
Painkiller Overuse Is Silently Harming Your Kidneys, Doctor Raises Alarm
While painkillers, especially non-steroidal anti-inflammatory drugs (NSAIDs), can provide relief from pain and inflammation, their overuse can severely impact kidney health.
-
New Study Explains Why Ozempic Doesn't Work For Everyone
A new study published in Genome Medicine details that Ozempic doesn't work for everyone in the same manner. Here is what you need to know about its mechanisms and why making science-based medical decisions is important.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
With Rs 13,000-25,000 Per Dose, Weight-Loss Drugs Are Changing Indian Weddings For Brides
The lowest Mounjaro injection pen dose sells for Rs 13,125 per month, while the highest dose costs Rs 25,781. Novo is selling the lowest Wegovy dose for Rs 5,660 and the highest for Rs 16,400 a month
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Metformin Does More Than Control Blood Sugar: New Research Reveals The Diabetes Drug's Negative Brain Impacts
A new study reveals metformin acts directly on the brain, raising fresh concerns about its wider effects. While effective for diabetes, experts warn of potential cognitive, neurological and metabolic risks, especially with long-term or unsupervised u
-
Common Diabetes Drug Metformin Works By Acting On Brain: Study
While diabetes medications are not considered as targeting the brain, the study, published in the journal Science Advances, shows that metformin has been influencing brain pathways all along, the researchers said.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
"Ozempic Personality" And The Dopamine Shift: The Mental Health Side Effects Of Using Ozempic For Weight Loss
Ozempic personality is a psychological impact of using Ozempic for weight loss. You need to know the possible side effects on your mental health to be careful.
-
Painkiller Overuse Is Silently Harming Your Kidneys, Doctor Raises Alarm
While painkillers, especially non-steroidal anti-inflammatory drugs (NSAIDs), can provide relief from pain and inflammation, their overuse can severely impact kidney health.
